Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12435909 | 0.78 | ATM (0.52) | HTTSMN1; SMN2MAPTMAPK1AHR | |
| SCHEMBL12435989 | 0.78 | SMN1; SMN2 (0.58) | HTTSMN1; SMN2MAPTMAPK1ALDH1A1 | |
| SCHEMBL12435963 | 0.76 | MAPT (0.58) | HTTSMN1; SMN2MAPTMAPK1AHR | |
| SCHEMBL12435911 | 0.75 | KDM4E (0.45) | HTTSMN1; SMN2MAPTMAPK1AHR | |
| SCHEMBL12436008 | 0.74 | SMN1; SMN2 (0.56) | HTTSMN1; SMN2MAPK1ALDH1A1NPSR1 | |
| SCHEMBL12435938 | 0.74 | HTT (0.43) | HTTSMN1; SMN2MAPTMAPK1AHR | |
| SCHEMBL12435992 | 0.74 | SMN1; SMN2 (0.45) | HTTSMN1; SMN2MAPTMAPK1AHR | |
| SCHEMBL12435966 | 0.73 | MAPT (0.50) | HTTSMN1; SMN2MAPTMAPK1AHR | |
| SCHEMBL12435912 | 0.73 | HTT (0.44) | HTTSMN1; SMN2MAPTMAPK1AHR | |
| SCHEMBL12435910 | 0.73 | KMT2A (0.44) | HTTSMN1; SMN2MAPTMAPK1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178108-A1 | Group of amino substituted benzoyl derivatives and their preparation and their use | Institute of Medicinal Biotechnology Academy of Medical Science (CN) | 2011-07-21 | — | — | US | disclosed |
| US-20110178108-A1 | Group of amino substituted benzoyl derivatives and their preparation and their use | Institute of Medicinal Biotechnology Academy of Medical Science (CN) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178108-A1 | Group of amino substituted benzoyl derivatives and their preparation and their use | CUL3, APOBEC3G, BRPF3 | HTT 1248/4885SMN1; SMN2 4598/4885MAPT 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.